Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
06/2000
06/27/2000US6080729 Polypeptides and polynucleotides used to screen for antibacterial compounds
06/27/2000US6080717 Treatment of individual having a need to inhibit a polypeptide, comprising administering a bactericidal antagonist of the polypeptide
06/27/2000US6080578 Cytopathic adenoviral E1B mutated viruses for therapy and prophylaxis of neoplasia
06/27/2000US6080558 Polynucleotide encoding human growth regulator protein
06/27/2000US6080383 Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic agents into radioactive toxic precipitates in the cancer
06/27/2000CA2198564C Method of reducing tissue damage associated with non-cardiac ischemia
06/23/2000CA2257001A1 Method and formulations for prevention of infection of mucosae and/or skin and development of a vaginal/ano-rectal applicator for the delivery of topical formulations
06/22/2000WO2000036421A1 Use of vascular endothelial growth factor (vegf)
06/22/2000WO2000036111A1 Therapeutic and diagnostic uses of protein tyrosine phosphatase tc-ptp
06/22/2000WO2000036103A1 Cytokine receptor chain
06/22/2000WO2000035948A1 Methods and compositions for treating disorders involving excitotoxicity
06/22/2000WO2000035946A1 Methods
06/22/2000WO2000035939A2 Connective tissue growth factor fragments and methods and uses thereof
06/22/2000WO2000035936A1 Connective tissue growth factor fragments and methods and uses thereof
06/22/2000WO2000035907A1 Imidazolones and their use in treating benign prostatic hyperplasia and other disorders
06/22/2000WO2000035900A1 Optical molecular sensors for cytochrome p450 activity
06/22/2000WO2000035891A1 Morpholinone and morpholine derivatives and uses thereof
06/22/2000WO2000035875A1 Arylpiperidine and aryl-1,2,5,6-tetrahydropyridine urea derivatives having 5ht1a receptor activity
06/22/2000WO2000035874A1 Arylpiperidine and aryl-1,2,5,6-tetrahydropyridine amide derivatives having 5ht1a receptor activity
06/22/2000WO2000035484A2 Methods and compositions for decreasing allergic reactions to surface allergens
06/22/2000WO2000035483A1 Methods and products for regulating lectin complement pathway associated complement activation
06/22/2000WO2000035469A2 hCG THERAPY FOR THE TREATMENT OF BREAST CANCER
06/22/2000WO2000035448A1 New pharmaceutical formulation
06/22/2000WO2000035444A1 USE OF η-TOCOPHEROL AND ITS OXIDATIVE METABOLITE LLU-α IN THE TREATMENT OF DISEASE
06/22/2000WO2000035437A2 Improving mental performance by increasing brain insulin sensitivity
06/22/2000WO2000035436A2 Treatment of arthritis with mek inhibitors
06/22/2000WO2000035435A1 Use of a mek inhibitor for preventing transplant rejection
06/22/2000WO2000035434A2 Compositions and methods for the treatment of anorectal disorders
06/22/2000WO2000035430A2 Homer a new target of treating psychiatric disorders
06/22/2000WO2000035429A1 Utilization of inhibitors of the kqt1 channel in order to produce a medicament for treating diseases which are caused by parasitic helminths and ectoparasites
06/22/2000WO2000035425A1 STABLE PHARMACEUTICAL FORMULATION COMPRISING A HMG-CoA REDUCTASE INHIBITOR
06/22/2000WO2000035423A1 Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same
06/22/2000WO2000035420A2 Stable surgical irrigating solutions
06/22/2000WO2000035409A2 Hiv-i fusion inhibition compounds
06/22/2000WO2000015244A3 Pharmaceutical preparation containing a cyclopeptide and a chemotherapeutic agent or an angiogenesis inhibitor
06/22/2000WO2000012703A3 Protein transport-associated molecules
06/22/2000WO2000012544A3 Novel irap-bp polypeptide and nucleic acid molecules and uses therefor
06/22/2000WO2000012048A3 Carbapenem antibacterial compositions and methods of treatment
06/22/2000WO2000009695A3 Drug targets in candida albicans
06/22/2000WO2000007624A3 Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix
06/22/2000WO2000002542A3 Agents with an antidepressive effect containing pramipexol and an additional antidepressant drug
06/22/2000WO1999054707A3 Fetal testing for prediction of low birth weight
06/22/2000WO1999048488A3 Methods for decreasing beta amyloid protein
06/22/2000CA2355650A1 Methods and compositions for decreasing allergic reactions to surface allergens
06/22/2000CA2355645A1 Increasing brain glucose utilization
06/22/2000CA2355607A1 Anti-ccr5 antibody
06/22/2000CA2355300A1 Utilization of inhibitors of the kqt1 channel in order to produce a medicament for treating diseases which are caused by parasitic helminths and ectoparasites
06/22/2000CA2355202A1 Imidazolones and their use in treating benign prostatic hyperplasia and other disorders
06/22/2000CA2355201A1 Morpholinone and morpholine derivatives and uses thereof
06/22/2000CA2354543A1 Compositions and methods for the treatment of anorectal disorders
06/22/2000CA2354456A1 Connective tissue growth factor fragments and methods and uses thereof
06/22/2000CA2354422A1 Connective tissue growth factor fragments and methods and uses thereof
06/22/2000CA2354323A1 Homer a new target of treating psychiatric disorders
06/22/2000CA2354061A1 Arylpiperidine and aryl-1,2,5,6-tetrahydropyridine amide derivatives having 5ht1a receptor activity
06/22/2000CA2353997A1 Therapeutic and diagnostic uses of protein tyrosine phosphatase tc-ptp
06/22/2000CA2352631A1 Optical molecular sensors for cytochrome p450 activity
06/22/2000CA2352613A1 New pharmaceutical formulation
06/22/2000CA2352570A1 Methods and compositions for treating disorders involving excitotoxicity
06/22/2000CA2351726A1 Hcg therapy for the treatment of breast cancer
06/22/2000CA2351400A1 Arylpiperidine and aryl-1,2,5,6-tetrahydropyridine urea derivatives having 5ht1a receptor activity
06/22/2000CA2346684A1 Use of a mek inhibitor for preventing transplant rejection
06/22/2000CA2346448A1 Treatment of arthritis with mek inhibitors
06/21/2000EP1010009A1 Automated robotic system and method for rapidly screening and identifying useful chemicals in liquid samples
06/21/2000EP1009854A1 A method of treating cancer
06/21/2000EP1009829A1 Adipocyte-specific protein homologs
06/21/2000EP1009824A1 COMPOSITIONS AND METHODS FOR MODULATING CELLULAR NF-kappaB ACTIVATION
06/21/2000EP1009811A2 New tissue-specific calpaines, their production and their use
06/21/2000EP1009765A1 EPO PRIMARY RESPONSE GENE, EPRG3Spt
06/21/2000EP1009760A2 Peroxisome-associated polypeptide, nucleotide sequence encoding said polypeptide and their uses in the diagnosis and/or the treatment of lung injuries and diseases, and of oxidative stress-related disorders
06/21/2000EP1009753A1 Hypoxia-regulated genes
06/21/2000EP1009524A1 Improvements in or relating to capsules
06/21/2000EP1009452A1 Dialysis solutions containing water soluble vitamins and nutrients
06/21/2000EP1009443A1 priA POLYPEPTIDES
06/21/2000EP1009432A1 Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses
06/21/2000EP1009427A1 USE OF FACTOR XIIIa INHIBITORS TO TREAT ATHEROSCLEROSIS
06/21/2000EP1009426A1 Method for treating a subject suffering from conditions associated with an extracellular zinc sphingomyelinase
06/21/2000EP1009421A1 Methods and compositions for enhanced wound healing
06/21/2000EP1009414A2 Novel pharmaceutical composition
06/21/2000EP1009411A1 Method and composition for treating sleep apnea
06/21/2000EP1009400A1 Combination therapy comprising atorvastatin and an antihypertensive agent
06/21/2000EP1009399A1 Gaba analogs to prevent and treat gastrointestinal damage
06/21/2000EP1009393A2 Transdermal therapeutic system comprising a reservoir-type pressure-sensitive adhesive layer and a back layer with uni-directional resilience
06/21/2000EP1009390A1 Prolonged anesthesia in joints and body spaces
06/21/2000EP1009383A1 Oral liposomal delivery system
06/21/2000EP1009232A1 Methods for treating insulin resistance and identifying patients at risk for the disease
06/21/2000DE19858372A1 Vitaminpräparat, Verfahren zu seiner Herstellung und seine Verwendung Vitamin preparation, process for its preparation and its use
06/21/2000DE19858253A1 Verwendung von Inhibitoren des KQt1-Kanals zur Herstellung eines Medikaments zur Behandlung von Krankheiten, die durch Helminthen und Ektoparasiten hervorgerufen werden Use of inhibitors of the KQT1 channel for preparing a medicament for the treatment of diseases which are caused by helminths and ectoparasites
06/20/2000US6077864 Cyclic sulfone derivatives
06/20/2000US6077849 Administering to a diabetic patient an antidiabetic fused bicyclic heteroaryl compound
06/20/2000US6077839 Method for reducing intraocular pressure in the mammalian eye by administration of gamma aminobutyric acid (GABA) agonists
06/20/2000US6077836 Peritoneal dialysis and compositions for use therein
06/20/2000US6077828 Method for the prevention and treatment of cachexia and anorexia
06/20/2000US6077822 Drug salts
06/20/2000US6077543 Atomizing solutions to produce drops; lung drug delivery
06/20/2000US6077539 Rapid bioavailability of metoclopramide; long acting non-steroidal antiinflammatory agent; free of ht3 receptor antagonists; side effect reduction
06/20/2000US6077530 Administering at different times to reduce side effects
06/20/2000US6077499 First conjugate of a tumor targeting moiety, a therapeutic agent, and first member of a binding pair; clearing agent; and second conjugate of the complementary binding member of the binding pair, and second therapeutic agent
06/20/2000CA2198536C Method of reducing tissue damage associated with ischemia
06/20/2000CA2011262C Use of mixed micelles
06/15/2000WO2000034791A1 Assays for compounds which increase phospholipase a2 activity
1 ... 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 ... 1151